Trial Profile
A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2012
Price :
$35
*
At a glance
- Drugs Belotecan (Primary)
- Indications Uterine cancer
- Focus Therapeutic Use
- 25 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual patients number is 16 as reported by ClinicalTrials.gov.